These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 20043814)

  • 1. Up-regulation of hypoxia-inducible factor (HIF)-1α and HIF-target genes in cortical neurons by the novel multifunctional iron chelator anti-Alzheimer drug, M30.
    Avramovich-Tirosh Y; Bar-Am O; Amit T; Youdim MB; Weinreb O
    Curr Alzheimer Res; 2010 Jun; 7(4):300-6. PubMed ID: 20043814
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The novel multi-target iron chelator, M30 modulates HIF-1α-related glycolytic genes and insulin signaling pathway in the frontal cortex of APP/PS1 Alzheimer's disease mice.
    Mechlovich D; Amit T; Bar-Am O; Mandel S; Youdim MB; Weinreb O
    Curr Alzheimer Res; 2014 Feb; 11(2):119-27. PubMed ID: 24359498
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel molecular targets of the neuroprotective/neurorescue multimodal iron chelating drug M30 in the mouse brain.
    Kupershmidt L; Weinreb O; Amit T; Mandel S; Bar-Am O; Youdim MB
    Neuroscience; 2011 Aug; 189():345-58. PubMed ID: 21570450
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuroprotective and neuritogenic activities of novel multimodal iron-chelating drugs in motor-neuron-like NSC-34 cells and transgenic mouse model of amyotrophic lateral sclerosis.
    Kupershmidt L; Weinreb O; Amit T; Mandel S; Carri MT; Youdim MB
    FASEB J; 2009 Nov; 23(11):3766-79. PubMed ID: 19638399
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multi-target, neuroprotective and neurorestorative M30 improves cognitive impairment and reduces Alzheimer's-like neuropathology and age-related alterations in mice.
    Kupershmidt L; Amit T; Bar-Am O; Weinreb O; Youdim MB
    Mol Neurobiol; 2012 Aug; 46(1):217-20. PubMed ID: 22847630
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The novel multi-target iron chelating-radical scavenging compound M30 possesses beneficial effects on major hallmarks of Alzheimer's disease.
    Kupershmidt L; Amit T; Bar-Am O; Youdim MB; Weinreb O
    Antioxid Redox Signal; 2012 Sep; 17(6):860-77. PubMed ID: 22360429
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular targets of the multifunctional iron-chelating drug, M30, in the brains of mouse models of type 2 diabetes mellitus.
    Mechlovich D; Amit T; Bar-Am O; Weinreb O; Youdim MB
    Br J Pharmacol; 2014 Dec; 171(24):5636-49. PubMed ID: 25073425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuroprotection by the multitarget iron chelator M30 on age-related alterations in mice.
    Kupershmidt L; Amit T; Bar-Am O; Youdim MB; Weinreb O
    Mech Ageing Dev; 2012 May; 133(5):267-74. PubMed ID: 22426424
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel antioxidant multitarget iron chelator M30 protects hepatocytes against ethanol-induced injury.
    Xiao J; Lv Y; Lin B; Tipoe GL; Youdim MB; Xing F; Liu Y
    Oxid Med Cell Longev; 2015; 2015():607271. PubMed ID: 25722794
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multi target neuroprotective and neurorestorative anti-Parkinson and anti-Alzheimer drugs ladostigil and m30 derived from rasagiline.
    Youdim MB
    Exp Neurobiol; 2013 Mar; 22(1):1-10. PubMed ID: 23585716
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The path from anti Parkinson drug selegiline and rasagiline to multifunctional neuroprotective anti Alzheimer drugs ladostigil and m30.
    Youdim MB
    Curr Alzheimer Res; 2006 Dec; 3(5):541-50. PubMed ID: 17168653
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypoxia-inducible factors as neuroprotective agent in Alzheimer's disease.
    Ashok BS; Ajith TA; Sivanesan S
    Clin Exp Pharmacol Physiol; 2017 Mar; 44(3):327-334. PubMed ID: 28004401
    [TBL] [Abstract][Full Text] [Related]  

  • 13. From anti-Parkinson's drug rasagiline to novel multitarget iron chelators with acetylcholinesterase and monoamine oxidase inhibitory and neuroprotective properties for Alzheimer's disease.
    Zheng H; Amit T; Bar-Am O; Fridkin M; Youdim MB; Mandel SA
    J Alzheimers Dis; 2012; 30(1):1-16. PubMed ID: 22387411
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases.
    Youdim MB; Fridkin M; Zheng H
    Mech Ageing Dev; 2005 Feb; 126(2):317-26. PubMed ID: 15621213
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The novel multitarget iron chelating and propargylamine drug M30 affects APP regulation and processing activities in Alzheimer's disease models.
    Amit T; Bar-Am O; Mechlovich D; Kupershmidt L; Youdim MBH; Weinreb O
    Neuropharmacology; 2017 Sep; 123():359-367. PubMed ID: 28571715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multifunctional neuroprotective derivatives of rasagiline as anti-Alzheimer's disease drugs.
    Weinreb O; Mandel S; Bar-Am O; Yogev-Falach M; Avramovich-Tirosh Y; Amit T; Youdim MB
    Neurotherapeutics; 2009 Jan; 6(1):163-74. PubMed ID: 19110207
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protection from oxidative stress-induced apoptosis in cortical neuronal cultures by iron chelators is associated with enhanced DNA binding of hypoxia-inducible factor-1 and ATF-1/CREB and increased expression of glycolytic enzymes, p21(waf1/cip1), and erythropoietin.
    Zaman K; Ryu H; Hall D; O'Donovan K; Lin KI; Miller MP; Marquis JC; Baraban JM; Semenza GL; Ratan RR
    J Neurosci; 1999 Nov; 19(22):9821-30. PubMed ID: 10559391
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases: in vitro studies on antioxidant activity, prevention of lipid peroxide formation and monoamine oxidase inhibition.
    Zheng H; Gal S; Weiner LM; Bar-Am O; Warshawsky A; Fridkin M; Youdim MB
    J Neurochem; 2005 Oct; 95(1):68-78. PubMed ID: 16181413
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Propargylamine containing compounds as modulators of proteolytic cleavage of amyloid-beta protein precursor: involvement of MAPK and PKC activation.
    Bar-Am O; Amit T; Weinreb O; Youdim MB; Mandel S
    J Alzheimers Dis; 2010; 21(2):361-71. PubMed ID: 20555137
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Promises of novel multi-target neuroprotective and neurorestorative drugs for Parkinson's disease.
    Youdim MB; Kupershmidt L; Amit T; Weinreb O
    Parkinsonism Relat Disord; 2014 Jan; 20 Suppl 1():S132-6. PubMed ID: 24262165
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.